Merck and Sun sign pact

Tuesday, April 26, 2011 11:41 AM

Merck and India-based Sun Pharmaceutical Industries have collaborated regarding rights to Merck’s diabetes drug Januvia, according to Pharma Times.

Merck and Sun have signed “an India-specific strategic partnership agreement” which states Sun will have the right to market, promote and distribute the dipeptidyl peptidase-4 inhibitor Januvia (sitagliptin) and Janumet (sitagliptin plus metformin), under different brand names.

K.G. Ananthakrishnan, managing director of Merck, Sharp & Dohme in India, indicated that the partnership will increase access to diabetic drugs in a country with “high disease burden of type 2 diabetes.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs